Skip to content

The effects of an exercise intervention on pulmonary function, respiratory muscle strength, aerobic capacity and perception of breathlessness in a representative population of patients with Idiopathic Parkinson's Disease

The effects of an exercise intervention on pulmonary function, respiratory muscle strength, aerobic capacity and perception of breathlessness in a representative population of patients with Idiopathic Parkinson's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13611537
Enrollment
100
Registered
2012-10-05
Start date
2012-08-15
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Dementias and Neurodegenerative Diseases Research Network

Interventions

Exercise Programme, 30 particpants randomised 1:1 control:intervention groups. The 15 in the intervention group will have a 3x weekly structured exercise intervention for 12 weeks.

Sponsors

Northumbria Healthcare NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Idiopathic Parkinson?s Disease by the UK PD Society Brain Bank Criteria 2. Hoehn and Yahr Stage I-IV (I-III for RCT) 3. Ability to provide written informed consent 4. Aged 18 years or over

Exclusion criteria

Exclusion criteria: 1. Other forms of Parkinsonism e.g. drug induced 2. Significant medical conditions which would preclude lung function testing 3. Significant medical conditions which would preclude exercise (RCT group) 4. Pregnancy 5. Recent diagnosis of a blood clot, deep vein thrombosis, pulmonary embolism or myocardial infarction 6. Unstable cardiac status, haemoptysis, pneumothorax, thoracic, abdominal or cerebral aneurysm 7. Recent eye, thoracic or abdominal surgery

Design outcomes

Primary

MeasureTime frame
Aerobic Capacity at baseline and end of 12 weeks

Secondary

MeasureTime frame
Pulmonary Function at baseline and end of 12 weeks

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026